Regeneron: Amgen’s Eylea Biosimilar Looks To Have An ‘Inferior Profile’
Originator Calls Out ‘Limited Data’ From Clinical Trials, ‘Safety Looks Worse’
Regeneron has taken a further swipe at Amgen after the biosimilars sponsor surprised the market by launching the first US rival to Eylea at-risk last month.
